Eli Lilly acquires SiteOne Therapeutics
Eli Lilly and Company and SiteOne Therapeutics, , a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, announced a definitive agreement for Lilly to acquire SiteOne
“The global...






